Skip to main content
APOLLOHOSP · Health Care · 2026-08-21

Apollo Hospitals Enterprise Ltd

4.8WatchEven +1.2Stage 2 · wk 19In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹8,693
-0.48% today
₹1,24,992 Cr · Large cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.

Visit company website →
P/E (TTM)
61.1
Forward 38.7
Earnings Growth (YoY)
+35.6%
Revenue +18.1%
ROE
+21.5%
Profit margin +7.7%
Dividend Yield
0.24%
P/B 12.5
vs 52W High
-3.9%
₹6,784.5 lo₹9,050 hi
3.9% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 19
1w13w26w
Week 19 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
11.1%
200 DMA: ₹7,826.4 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.55x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -0.7% vs MA50 +2.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #50 of 84 Stage 2 stocks in Health Care by RS.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
55.6%
20d Δ
-7.4pp
1M return
-2.8%
3M return
+2.0%
Industry Stage-2 % · last 20 days
Ranks #7 of 15 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 14w
S2 25w
S2 28w
S2 24w
S2 19w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 14w → S3 9w → S2 25w → S3 11w → S2 28w → S3 5w → S4 8w → S1 5w → S2 24w → S3 7w → S4 7w → S1 6w → S2 19w current
Total tracked: 168 weeks across 14 stage runs.
1M
-1.9%
3M
+4.0%
6M
+14.1%
YTD
+22.9%
1Y
+11.6%
Scan Membership
Breakout Watch
Latest: 2026-04-13
3 appearances in last 60 days. First seen: 2024-07-19.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 19 · Vol x
2026-08-20S2
Wk 18 · Vol x
2026-08-19S2
Wk 18 · Vol x
2026-08-18S2
Wk 18 · Vol x
2026-08-17S2
Wk 18 · Vol x
2026-08-14S2
Wk 18 · Vol x
2026-08-13S2
Wk 17 · Vol x
2026-08-12S2
Wk 17 · Vol x
2026-08-11S2
Wk 17 · Vol x
2026-08-10S2
Wk 17 · Vol x
2026-08-07S2
Wk 17 · Vol x
2026-08-06S2
Wk 16 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹8,764.3
200 DMA
₹7,826.4
52W High
₹9,050
52W Low
₹6,784.5
5D Low
₹8,693
Resistance levels (recent highs)
20d High
₹9,050
60d High
₹9,050
120d High
₹9,050
250d High
₹9,050
Next resistance
+4.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.